- Home
- EXPI vs MNKD Comparison
EXPI vs MNKD Comparison
Compare EXPI & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXPI
- MNKD
- Stock Information
- Founded
- EXPI 2008
- MNKD 1991
- Country
- EXPI United States
- MNKD United States
- Employees
- EXPI N/A
- MNKD N/A
- Industry
- EXPI Real Estate
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- EXPI Finance
- MNKD Health Care
- Exchange
- EXPI Nasdaq
- MNKD Nasdaq
- Market Cap
- EXPI 2.2B
- MNKD 1.8B
- IPO Year
- EXPI N/A
- MNKD 2004
- Fundamental
- Price
- EXPI $13.25
- MNKD $6.90
- Analyst Decision
- EXPI Hold
- MNKD Strong Buy
- Analyst Count
- EXPI 2
- MNKD 5
- Target Price
- EXPI $13.50
- MNKD $8.40
- AVG Volume (30 Days)
- EXPI 818.9K
- MNKD 3.0M
- Earning Date
- EXPI 11-07-2024
- MNKD 11-07-2024
- Dividend Yield
- EXPI 1.52%
- MNKD N/A
- EPS Growth
- EXPI N/A
- MNKD N/A
- EPS
- EXPI N/A
- MNKD 0.08
- Revenue
- EXPI $4,458,228,000.00
- MNKD $267,200,000.00
- Revenue This Year
- EXPI $8.76
- MNKD $46.83
- Revenue Next Year
- EXPI $7.62
- MNKD $14.40
- P/E Ratio
- EXPI N/A
- MNKD $87.03
- Revenue Growth
- EXPI 5.50
- MNKD 51.35
- 52 Week Low
- EXPI $8.91
- MNKD $3.17
- 52 Week High
- EXPI $17.11
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- EXPI 47.87
- MNKD 51.11
- Support Level
- EXPI $12.32
- MNKD $6.67
- Resistance Level
- EXPI $14.85
- MNKD $7.04
- Average True Range (ATR)
- EXPI 0.80
- MNKD 0.34
- MACD
- EXPI -0.13
- MNKD -0.06
- Stochastic Oscillator
- EXPI 32.07
- MNKD 28.43
About EXPI eXp World Holdings Inc.
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services. The company mainly operates in the United States and Canada, and it also has operations in the United Kingdom, Australia, South Africa, France, India, Portugal, and Mexico, among others.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.